<DOC>
	<DOC>NCT00880360</DOC>
	<brief_summary>This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.</brief_summary>
	<brief_title>A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Able to provide informed consent Not on Immune modulating drugs Life expectancy less than 6 months Unable to tolerate phlebotomy Germ cell or stromal cell cancers of the ovaries Active autoimmune disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>FIGO (International Federation of Gynecology and Obstetrics )Stage III or Stage IV</keyword>
	<keyword>Extraovarian Peritoneal Cancer</keyword>
	<keyword>Fallopian Tube Carcinoma Failing</keyword>
</DOC>